Smith Group Asset Management’s Array Biopharma Inc ARRY Stock Holding History

Smith Group Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,620	Closed	-$307K	–	471
2019 Q2	$307K	Hold	6,620	–	–	0.01%	176
2019 Q1	$161K	Sell	6,620 -20,700	-76%	-$431K	0.01%	231
2018 Q4	$389K	Sell	27,320 -600	-2%	-$9.1K	0.01%	203
2018 Q3	$424K	Buy	27,920 +7,400	+36%	+$113K	0.01%	203
2018 Q2	$344K	Buy	20,520 +480	+2%	+$7.63K	0.01%	212
2018 Q1	$327K	Buy	+20,040	New	+$321K	0.01%	215
2013 Q3	–	Sell	-304,657	Closed	-$1.38M	–	452
2013 Q2	$1.38M	Buy	+304,657	New	+$1.64M	0.06%	172

Other funds holding ARRY

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Smith Group Asset Management's ARRY Position: Q3 2019 in Review

Smith Group Asset Management sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 6,620 shares — an estimated $307K sold.

Smith Group Asset Management first reported a position in ARRY in Q2 2013 and held it in 7 quarters. The position peaked at $1.38M in Q2 2013. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

Smith Group Asset Management reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
Smith Group Asset Management sold 6,620 Array Biopharma Inc shares in Q3 2019, an estimated $307K.
Smith Group Asset Management first reported a position in Array Biopharma Inc in Q2 2013 and held it in 7 quarters.
Smith Group Asset Management's Array Biopharma Inc position peaked at $1.38M in Q2 2013.
1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Smith Group Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.